LEUKEMIA AND LYMPHOMA SOCIETY: FDA APPROVES NEW DRUG FOR THE MOST COMMON FORM OF LEUKEMIA IN ADULTS
December 09, 2023
December 09, 2023
RYE BROOK, New York, Dec. 9 -- The Leukemia and Lymphoma Society issued the following news release:
The U.S. Food and Drug Administration has approved pirtobrutinib (Jaypirca(TM)) for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has worsened or returned despite at least two earlier forms of treatment. Pirtobrutinib was approved earlier this year for the treatment of relapsed/refractory mantle cell lymphoma.
Pir . . .
The U.S. Food and Drug Administration has approved pirtobrutinib (Jaypirca(TM)) for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has worsened or returned despite at least two earlier forms of treatment. Pirtobrutinib was approved earlier this year for the treatment of relapsed/refractory mantle cell lymphoma.
Pir . . .